CUEDC2 Antibody recognizes endogenous levels of total CUEDC2 protein.
Source / Purification
Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues near the carboxy terminus of human CUEDC2 protein. Antibodies are purified by protein A and peptide affinity chromatography.
Background
CUE domain-containing 2 (CUEDC2) protein is involved in regulating many cellular events including cell cycle regulation (1) and inflammation (2). Research studies have shown that CUEDC2 is highly expressed in many types of tumors, suggesting this protein may play a role in tumorigenesis (1,3). CUEDC2 is activated in early mitosis when it is phosphorylated by Cdk1 at Ser110. Phosphorylated CUEDC2 binds to Cdc20, which leads to the release of the anaphase-promoting complex/cyclosome (APC/C) from checkpoint inhibition, initiating anaphase. CUEDC2 is then dephosphorylated when cells exit mitosis (1). CUEDC2 is also an inhibitor of IKKα and IKKβ activation (2) as well as Jak1/Stat3 signaling (4). Research indicates that inappropriate regulation of CUEDC2 may contribute to tumor development by causing chromosome instability (1). Multiple studies have reported that CUEDC2 plays a role in the downregulation of progesterone receptor and estrogen receptor α, impairing the effects of progesterone on breast cancer cell growth. Conversely, research studies have shown that CUEDC2 and HER2 expression have a significant positive correlation in breast cancers, leading investigators to suggest that CUEDC2 could be an important target for breast cancer therapy (3,5).